Neumora Therapeutics reports Q1 EPS (42c), consensus (38c)

“Our vision in building Neumora is to make a difference for people living with brain diseases. With our diverse, industry-leading pipeline, multiple upcoming clinical catalysts, experienced team and strong financial foundation, we are making important progress towards achieving that goal,” said Paul L. Berns, chairman and chief executive officer, Neumora. “We are advancing enrollment for the Phase 1b signal-seeking study of NMRA-511 in Alzheimer’s disease agitation, have taken important steps to help optimize the navacaprant program in major depressive disorder, and expect to bring an M4 PAM into the clinic in the coming months. I envision that this will be a productive year with updates across several programs in our portfolio, and we look forward to sharing more in the coming quarters.”